Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update

Ultragenyx Pharma (RARE) Misses Q2 EPS by 51c; Reaffirms Product Revenue Guidance

July 28, 2022 4:42 PM EDT

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($2.26), $0.51 worse than the analyst estimate of ($1.75). Revenue for the quarter came in at $89.3 million versus the consensus estimate of $87.65 million.

GUIDANCE:

Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260... More